General Information, Appendix, Index

Total Page:16

File Type:pdf, Size:1020Kb

General Information, Appendix, Index GENERAL INFORMATION injection device— Equilibration temperature A constant temperature of G1 Physics and Chemistry for inside vial about 809C Equilibration time for 60 minutes inside vial Guideline for Residual Solvents Transfer-line temperature A constant temperature of about 859C and Models for the Residual Carrier gas Nitrogen Solvents Test Pressurisation time 30 seconds Injection volume of sample 1.0 mL 1. Guideline for Residual Solvents (ii) Operating conditions (2) for the head-space sample Refer to the Guideline for Residual Solvents in Phar- injection device— maceuticals (PAB/ELD NotificationNo.307;datedMarch Equilibration temperature A constant temperature of 30, 1998). for inside vial about 1059C Since the acceptable limits of residual solvents recom- Equilibration time for 45 minutes mended in the Guideline were estimated to keep the safety of inside vial patients, the levels of residual solvents in pharmaceuticals Transfer-line temperature A constant temperature of must not exceed the limits, except for in a special case. Phar- about 1109C maceutical manufacturers should assure the quality of their Carrier gas Nitrogen products by establishing their own specification limits or Pressurisation time 30 seconds manufacturing process control limits for residual solvents Injection volume of sample 1.0 mL present in their products in consideration of the limits (iii) Operating conditions (3) for the head-space sample recommended in the Guideline and the observed values in injection device— their products, and by performing the test with the products Equilibration temperature A constant temperature of according to the Residual Solvents Test. for inside vial about 809C Equilibration time for 45 minutes 2. Residual Solvents Test inside vial Generally, the test is performed by using gas chromato- Transfer-line temperature A constant temperature of graphy <2.02> as directed in the Residual Solvents Test about 1059C 2.46 < >. If only the class 3 solvents with low toxic potential to Carrier gas Nitrogen man are present in the products, Loss on Drying Test <2.41> Pressurisation time 30 seconds can be applied in place of gas chromatography, in which case Injection volume of sample 1.0 mL the limit value of residual solvents is not more than 0.5z. The test may also be performed according to the EP 3.2. Models for operating conditions and system suitability method (2.4.24 Identification and control of residual sol- of gas chromatography vents) or the USP method (<467> Residual Solvents). Even in (i) Test conditions (1) (A model described under Proce- this case, description should be in the JP style and the system dure A in the EP and the USP) suitability test should be performed according to the JP rule. Operating conditions— Detector: Hydrogen flame-ionization detector. 3. Models for the operating conditions and system suita- Column: Coat the inside wall of a fused silica tube, 0.32 bility of gas chromatography for residual solvents test mm (or 0.53 mm) in inside diameter and 30 m in length, to The following are typical examples of the operating condi- 1.8 mm(or3mm) thickness with 6z cyanopropylphenyl- tions of gas chromatography for residual solvents test, de- methyl silicon polymer for gas chromatography. Use a guard scribed in the EP and the USP, but these do not necessarily column if necessary. imply that other suitable operating conditions can not be Column temperature: Maintain at 409C for 20 minutes, used. In the operating conditions, generally, items required then increase to 2409Cat109C per minute if necessary, and for the test such as detector, column, column temperature, keep at 2409C for 20 minutes. injection port temperature, detector temperature, carrier Injection port temperature: A constant temperature of gas, flow rate, and time span of measurement should be spe- about 1409C. cified, and in the system suitability, items such as test for re- Detector temperature: A constant temperature of about quired detectability, system performance, and system repeat- 2509C. ability should be specified. The following are several models Carrier gas: Helium. for the operating conditions and the system suitability: Flow rate: 35 cm/second. 3.1. Models for operating conditions for a head-space Split ratio: 1:5. sample injection device (Models described in the EP and the System suitability— USP) System performance: When the procedure is run with the (i) Operating conditions (1) for the head-space sample standard solution under the above operating conditions, the 2135 2136 Physics and Chemistry / General Information JP XVI resolution between the peaks is not less than 1.0. (Note: In System repeatability: When the test is repeated 6 times the case that the number of substances to be tested is two or with the standard solution under the above operating condi- more.) tions, the relative standard deviation of the peak areas of the System repeatability: When the test is repeated 3 times substance to be tested is not more than 15z. with the standard solution under the above operating condi- tions, the relative standard deviation of the peak areas of the substance to be tested is not more than 15z. (ii) Test conditions (2) (A model described under Proce- Inductively Coupled Plasma Atomic dure B in the EP and the USP) Emission Spectrometry Operating conditions— Detector: Hydrogen flame-ionization detector. Inductively coupled plasma (ICP) atomic emission spec- Column: Coat the inside wall of a fused silica tube, 0.32 trometry is a method for qualitative and quantitative analy- mm (or 0.53 mm) in inside diameter and 30 m in length, to sis for the element in the sample specimen, which is nebu- 0.25 mm thickness with polyethylene glycol 20M for gas lized into argon plasma induced by radio frequency power, chromatography. Use a guard column if necessary. by measuring the wavelength and the intensity of the emis- Column temperature: Maintain at 509C for 20 minutes, sion spectra generated by the target element, atomized and then increase to 1659Cat69C per minute if necessary, and excited in the plasma. Argon gas plasma used in this method keep at 1659C for 20 minutes. is characteristic of higher temperature of 6000 ¿ 8000 K and Injection port temperature: A constant temperature of electronic density of 1015 cm-3. about 1409C. When the high energy is externally given to an atom, the Detector temperature: A constant temperature of about orbit transition of the most exterior electron is occurred and 2509C. attained to the excited state. When the excited state of atom Carrier gas: Helium. returns to the basic state, the energy obtained by the excita- Flow rate: 35 cm/second. tion is radiated as a light. The emitted light has an intrinsic Split ratio: 1:5. wave number n and wave length l, attributed to the individ- System suitability— ual element. Assuming the Plank constant h and the light System performance: When the procedure is run with the velocity c, the emitted light energy DE is expressed by the standard solution under the above operating conditions, the following formula. resolution between the peaks is not less than 1.0. (Note: In DE = hn = hc/l the case that the number of substances to be tested is two or more.) Since there are many of combinations of the orbit transi- System repeatability: When the test is repeated 3 times tion energy level of the most exterior electron and the emit- with the standard solution under the above operating condi- ted light energy, usually, there are plenty of spectral lines tions, the relative standard deviation of the peak areas of the emitted from an element, summing up every strong and substance to be tested is not more than 15z. weak emitted lights. However, the number of emitted lights (iii) Test conditions (3) (A model described in Method I of being in the ultra-violet and visible region and having suit- under Other Analytical Procedures in the USP) able detection sensitivity for qualitative and quantitative Operating conditions— analysis are limited to a certain number. Since the atomic Detector: Hydrogen flame-ionization detector. emission spectra give intrinsic wave number or wave length Column: Coat the inside wall of a fused silica tube, 0.53 for the respective element, many of elements contained in a mm in inside diameter and 30 m in length, to 5 mm thickness sample specimen can be identified by the spectroscopic with 5z phenyl-methyl silicon polymer for gas chromatog- analysis of the emitted lights. Furthermore, the quantitative raphy. If necessary use a guard column prepared by coating analysis for an element can also be done by measuring the the inside wall of a fused silica tube, 0.53 mm in inside diam- spectral intensity of the emitted light. eter and 5 m in length, to 5 mm thickness with 5z phenyl- The characteristics of ICP emission spectrometry are sum- methyl silicon polymer for gas chromatography. marized as follows; Column temperature: Maintain at 359C for 5 minutes, ( i ) Microanalysis for plenty of elements is possible. then increase to 1759Cat89C per minute, further increase to ( ii ) Analytical precision is high, since the stable plasma 2609Cat359C per minute if necessary, and keep at 2609C generation can be kept. for 16 minutes. (iii) Linearity of the calibration curve is ensured in the Injection port temperature: A constant temperature of wide range of 4 ¿ 5digit. about 709C. (iv) Multi-element simultaneous analysis is possible. Detector temperature: A constant temperature of about ( v ) Chemical interferences are almost negligible. 2609C. Carrier gas: Helium. The most serious problem in the ICP emission spectro- Flow rate: 35 cm/second. metry is that the spectral interferences are inevitable to this Split ratio: Splitless. analysis, and disturb the analysis for the target element. It System suitability— results from many of emitted spectral lines due to coexisting System performance: When the procedure is run with the elements, because the atomization and excitation of elements standard solution under the above operating conditions, the are done in very high temperature of plasma.
Recommended publications
  • Eperisone-Induced Anaphylaxis: Pharmacovigilance Data and Results of Allergy Testing
    Allergy Asthma Immunol Res. 2019 Jan;11(1):e18 https://doi.org/10.4168/aair.2019.11.e18 pISSN 2092-7355·eISSN 2092-7363 Original Article Eperisone-Induced Anaphylaxis: Pharmacovigilance Data and Results of Allergy Testing Kyung Hee Park,1,2 Sang Chul Lee,1,2 Ji Eun Yuk,2 Sung-Ryeol Kim,1,2 Jae-Hyun Lee,1,2 Jung-Won Park1,2* 1Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea 2Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea Received: Aug 6, 2018 ABSTRACT Revised: Sep 10, 2018 Accepted: Sep 22, 2018 Purpose: Eperisone is an oral muscle relaxant used in musculoskeletal disorders causing Correspondence to muscle spasm and pain. For more effective pain control, eperisone is usually prescribed Jung-Won Park, MD, PhD together with nonsteroidal anti-inflammatory drugs (NSAIDs). As such, eperisone may Division of Allergy and Immunology, have been overlooked as the cause of anaphylaxis compared with NSAIDs. This study aimed Department of Internal Medicine, Yonsei to analyze the adverse drug reaction (ADR) reported in Korea and suggest an appropriate University College of Medicine, 50-1 Yonsei-ro, diagnostic approach for eperisone-induced anaphylaxis. Seodaemun-gu, Seoul 03722, Korea. Tel: +82- 2-2228-1961; Fax: +82-2-393-6884; Methods: We reviewed eperisone-related pharmacovigilance data (Korea Institute of Drug E-mail: [email protected] Safety-Korea Adverse Event Reporting System [KIDS-KAERS]) reported in Korea from 2010 to 2015. ADRs with causal relationship were selected. Clinical manifestations, severity, Copyright © 2019 The Korean Academy of outcomes, and re-exposure information were analyzed.
    [Show full text]
  • Efficacy and Tolerability of Eperisone in Patients with Spastic Palsy: a Cross-Over, Placebo-Controlled Dose-Ranging Trial
    European Review for Medical and Pharmacological Sciences 2009; 13: 365-370 Efficacy and tolerability of eperisone in patients with spastic palsy: a cross-over, placebo-controlled dose-ranging trial N. BRESOLINA, C. ZUCCAB, A. PECORIC AInstitute of Clinical Neurology, University of Milan, I.R.C.C.S. Ospedale Maggiore Policlinico, Milan (Italy) BNeurophysiopathology Unit, IRCCS “E. Medea”, Bosisio Parini (LC) (Italy) CMedical Department Eisai Srl, San Donato Milanese, Milano (Italy) Abstract. – Background and Objectives: Introduction Central muscle relaxants are a clinical option in patients with spastic palsy. Eperisone is a cen- tral muscle relaxant used in several conditions, Spastic palsy is a clinical condition character- but its therapeutic potential in spastic palsy ized by a velocity-dependent increase of muscle needs to be verified. This dose-ranging trial tone due to “parapyramidal” disturbance of the compares two doses of eperisone in patients inhibitory afferents to the second motor neuron1. with spastic palsy associated to cerebral or spinal diseases. This condition may represent a major impedi- Patients and Methods: In this randomized, ment to a full functional recovery and social re- placebo-controlled, double-blind, three-way habilitation in patients with lesions of the pyra- cross-over study, patients (18-75 years) with midal system, which could follow different dis- spastic palsy received eperisone 150 mg/day, eases, as stroke or multiple sclerosis. eperisone 300 mg/day, or placebo for 8 weeks. Central muscle relaxants, such as baclofen, ti- Treatment periods lasted for 14 days. Objective zanidine, diazepam and dantrolene, represent an clinical parameters (intensity of spasticity and physiological reflexes) and functional parame- interesting clinical option in patients with spastic ters (walking capability, capability to climb palsy, since they reduce spasticity and improve stairs, rigidity) were measured.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL Et Al
    US 20140296.191A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL et al. (43) Pub. Date: Oct. 2, 2014 (54) COMPOSITIONS OF PHARMACEUTICAL (52) U.S. Cl. ACTIVES CONTAINING DETHYLENE CPC ............... A61K 47/10 (2013.01); A61 K9/0019 GLYCOL MONOETHYLETHER OR OTHER (2013.01); A61 K9/0048 (2013.01); A61 K ALKYL DERVATIVES 45/06 (2013.01) USPC ........... 514/167: 514/177; 514/178: 514/450; (71) Applicant: THEMIS MEDICARE LIMITED, 514/334: 514/226.5: 514/449; 514/338; Mumbai (IN) 514/256; 514/570; 514/179; 514/174: 514/533; (72) Inventors: Dinesh Shantilal PATEL, Mumbai (IN); 514/629; 514/619 Sachin Dinesh PATEL, Mumbai (IN); Shashikant Prabhudas KURANI, Mumbai (IN); Madhavlal Govindlal (57) ABSTRACT PATEL, Mumbai (IN) (73) Assignee: THEMIS MEDICARE LIMITED, The present invention relates to pharmaceutical compositions Mumbai (IN) of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl (21) Appl. No.: 14/242,973 ether or other alkyl derivatives thereofas a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene (22) Filed: Apr. 2, 2014 glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or as a solvent system in preparation of Such (30) Foreign Application Priority Data pharmaceutical compositions. The pharmaceutical composi Apr. 2, 2013 (IN) ......................... 1287/MUMA2013 tions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formu Publication Classification lations containing such pharmaceutical actives and are Suit able for use as injectables for intravenous and intramuscular (51) Int. Cl. administration, as well as for use as a preformed solution/ A647/ (2006.01) liquid for filling in and preparation of capsules, tablets, nasal A6 IK 45/06 (2006.01) sprays, gargles, dermal applications, gels, topicals, liquid oral A6 IK9/00 (2006.01) dosage forms and other dosage forms.
    [Show full text]
  • Efficacy and Tolerability of Eperisone Versus Tizanidine in Patients Suffering from Low Back Pain with Muscle Spasm
    International Journal of Research in Medical Sciences Khan AF et al. Int J Res Med Sci. 2017 Jun;5(6):2694-2700 www.msjonline.org pISSN 2320-6071 | eISSN 2320-6012 DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20172472 Original Research Article Efficacy and tolerability of eperisone versus tizanidine in patients suffering from low back pain with muscle spasm Abdul F. Khan1*, Khaneta Parveen2, Abdul S. Khan3 1Consultant Physician and Diabetologist, Mumbai, Maharashtra, India 2Department of Pathology and Blood Bank, Kohinoor Hospital, Mumbai, Maharashtra, India 3Department of Cardiology, Prince Sultan Hospital, Riyadh, KSA Received: 05 April 2017 Accepted: 28 April 2017 *Correspondence: Dr. Abdul F. Khan, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Low back pain (LBP), a high prevalent condition, is usually associated with 'muscle spasm' that is responsible for giving rise to pain. Eperisone hydrochloride is widely used for treatment associated muscle stiffness and pain. The aim of the study was to compare the efficacy and safety of eperisone tablets 50 mg three times daily versus tizanidine 2 mg tablets thrice daily for the treatment of low back pain with muscle spasm. Methods: The study was carried in 50 patients from a private hospital at Mumbai. Only patients satisfying the inclusion criteria were enrolled into the study. Subjects suffering from low back pain with spasm were divided in two groups.
    [Show full text]
  • ( 12 ) United States Patent
    US010131766B2 (12 ) United States Patent (10 ) Patent No. : US 10 , 131, 766 B2 Hazen et al. (45 ) Date of Patent: Nov . 20 , 2018 ( 54 ) UNSATURATED POLYESTER RESIN 6 ,619 ,886 B1 9 /2003 Harrington 6 ,692 , 802 B1 2 / 2004 Nava SYSTEM FOR CURED IN - PLACE PIPING 7 , 135 ,087 B2 11/ 2006 Blackmore et al. 7 ,799 ,228 B2 9 /2010 Bomak et al . (71 ) Applicant : Interplastic Corporation , Saint Paul, 8 , 047, 238 B2 11/ 2011 Wiessner et al . MN (US ) 8 ,053 ,031 B2 11/ 2011 Stanley et al. 8 ,092 ,689 B2 1 / 2012 Gosselin (72 ) Inventors : Benjamin R . Hazen , Roseville , MN 8 , 298 , 360 B2 10 / 2012 Da Silveira et al. 8 ,418 , 728 B1 4 / 2013 Kiest , Jr . (US ) ; David J . Herzog , Maple Grove , 8 ,586 ,653 B2 11 / 2013 Klopsch et al. MN (US ) ; Louis R . Ross, Cincinnati , 8 ,636 , 869 B2 1 / 2014 Wiessner et al . OH (US ) ; Joel R . Weber , Moundsview , 8 ,741 , 988 B2 6 /2014 Klopsch et al. MN (US ) 8 , 877 , 837 B2 11/ 2014 Yu et al. 9 ,068 , 045 B2 6 /2015 Nava et al. 9 ,074 , 040 B2 7 / 2015 Turshani et al. ( 73 ) Assignee : Interplastic Corporation , St. Paul , MN 9 , 150 , 709 B2 10 / 2015 Klopsch et al . (US ) 9 , 207 , 155 B1 12 / 2015 Allouche et al. 9 ,273 ,815 B2 3 / 2016 Gillanders et al. ( * ) Notice : Subject to any disclaimer, the term of this 9 , 371, 950 B2 6 / 2016 Hairston et al. patent is extended or adjusted under 35 9 , 550 , 933 B2 1 /2017 Chatterji et al .
    [Show full text]
  • WO 2012/172413 Al 20 December 2012 (20.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/172413 Al 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: (74) Agent: NAIR, Manoj Vasudevan; M/s Lex Orbis (Intel A61K 9/20 (2006.01) A61K 31/4453 (2006.01) lectual Property Practice), 709/710, Tolstoy House, 15-17 A61K 31/196 (2006.01) A61K 47/12 (2006.01) Tolstoy Marg, New Delhi 110 001 (IN). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/IB20 12/00 1159 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) Date: International Filing CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 15 June 2012 (15.06.2012) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (26) Publication Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (30) Priority Data: OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 1759/MUM/201 1 16 June 201 1 (16.06.201 1) IN SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Treatment for Acute Pain: an Evidence Map Technical Brief Number 33
    Technical Brief Number 33 R Treatment for Acute Pain: An Evidence Map Technical Brief Number 33 Treatment for Acute Pain: An Evidence Map Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-0000-81 Prepared by: Minnesota Evidence-based Practice Center Minneapolis, MN Investigators: Michelle Brasure, Ph.D., M.S.P.H., M.L.I.S. Victoria A. Nelson, M.Sc. Shellina Scheiner, PharmD, B.C.G.P. Mary L. Forte, Ph.D., D.C. Mary Butler, Ph.D., M.B.A. Sanket Nagarkar, D.D.S., M.P.H. Jayati Saha, Ph.D. Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19(20)-EHC022-EF October 2019 Key Messages Purpose of review The purpose of this evidence map is to provide a high-level overview of the current guidelines and systematic reviews on pharmacologic and nonpharmacologic treatments for acute pain. We map the evidence for several acute pain conditions including postoperative pain, dental pain, neck pain, back pain, renal colic, acute migraine, and sickle cell crisis. Improved understanding of the interventions studied for each of these acute pain conditions will provide insight on which topics are ready for comprehensive comparative effectiveness review. Key messages • Few systematic reviews provide a comprehensive rigorous assessment of all potential interventions, including nondrug interventions, to treat pain attributable to each acute pain condition. Acute pain conditions that may need a comprehensive systematic review or overview of systematic reviews include postoperative postdischarge pain, acute back pain, acute neck pain, renal colic, and acute migraine.
    [Show full text]
  • Efficacy and Safety of Eperisone in Patients with Low Back Pain: a Double Blind Randomized Study
    European Review for Medical and Pharmacological Sciences 2008; 12: 229-235 Efficacy and safety of eperisone in patients with low back pain: a double blind randomized study P. CABITZA, P. RANDELLI Clinica Ortopedica, Dipartimento di Scienze Medico-Chirurgiche dell’Università degli Studi di Milano, San Donato Milanese (Italy) Abstract. – Eperisone hydrochloride (4’- Introduction ethyl-2-methyl-3-piperidinopropiophenone hy- drochloride) is an antispastic agent used for treatment of diseases characterized by muscle Acute low back pain is a leading reason for stiffness and pain. primary care visits with a generally favourable The aim of this research was to investigate short-term prognosis. Medications with good evi- the efficacy of eperisone in patients with acute low back pain and spasticity of spinal muscles. dence of short-term efficacy include non- The study design was a randomized, double- steroidal anti-inflammatory drugs (NSAIDs), blind (double-dummy) study in 160 patients with paracetamol and centrally active skeletal muscle low back pain and no Rx finding of major spinal relaxants. However, evidence is insufficient to diseases, randomly assigned to a treatment with identify one medication as offering a clear over- oral eperisone 100 mg three times daily (t.i.d.) or all net advantage because of complex tradeoffs thiocolchicoside 8 mg twice daily (b.i.d.) for 12 between benefits and harms. Therefore, an un- consecutive days. Analgesic activity was evaluated by scoring derstanding of mechanisms underlying the pain “spontaneous pain” (VAS) and pain on move- is essential for any physician who sees and treats ment and pression (4-digit scale), while muscle patients with acute low back pain1.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Supplement II to the Japaneses Pharmacopoeia Fourteenth Edition
    The Ministry of Health, Labour and Welfare Ministerial Notiˆcation No. 461 In accordance with the provisions of Article 41, Paragraph 1 of the Pharmaceutical AŠairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Phar- macopoeia (Ministerial Notiˆcation No. 111, 2001) as follows, and the revised Japanese Pharmacopoeia shall come into eŠect on January 1, 2005, [including dele- tion from O‹cial Monographs fro Part II in The Japanese Pharmacopoeia, Four- teenth Edition of the articles of Absorbent Cotton, Puriˆed Absorbent Cotton, Sterile Absorbent Cotton, Sterile Puriˆed Absorbent Cotton and Absorbent Gauze and Sterile Absorbent Gauze (hereinafter referred to as ``sanitary materials'')]. Provi- so: With respect to the drugs which are included in the Japanese Pharmacopoeia (hereinafter referred to as ``the old Japanese Pharmacopoeia'') [limited to those included in the Japanese Pharmacopoeia whose standards are changed with this notiˆcation published (hereinafter referred to as ``the new Japanese Phar- macopoeia'')] and those which are approved as of January 1, 2005 pursuant to the provisions of Article 14, Paragraph 1 of this Law (including cases where it shall apply mutatis mutandis under Article 23 of this Law; the same hereinafter) [including the drugs designated as those exempted from approval (hereinafter referred to as ``the drugs exempted from approval'') among the drugs etc. designated by the Minister of Health, Labour and Welfare as those exempted from manufacturing or import approval pursuant to the provisions of Article 14, Paragraph 1 of the Pharmaceutical AŠairs Law (Ministerial Notiˆcation No. 104, 1994), the standards established in the old Japanese Pharmacopoeia (limited to the standards for the relevant drugs) shall be recognized, up to June 30, 2006, as the standards established in the new Japanese Pharmacopoeia.
    [Show full text]
  • Pain Management
    Pain management Preeyaphan Arunakul MD FRCAT Department of Anesthesia Faculty of Medicine, Thammasat University Definition “An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage.” Classification of pain by time • Acute pain - Pain less than 12 weeks • Chronic pain - Pain longer than 12 weeks Nociceptive Nonnociceptive Somatic Visceral Neuropathic Psychogenic sharp, dull Poorly localized, Burning, electrical -Rarely pure aching deep squeezing, (lancinating), -No nociceptive or crampy numbing, neuropathic mechanism allodynia, can be identified -Myofascial hyperalgesia -With sufficient -Metastatic -Small bowel psychogenic symptoms bone pain obstruction -Postsurgical -Carcinomatosis -Trigeminal neuralgia -Arthritis peritonii -Postherpetic neuralgia -Painful peripheral neuropathy NSAIDs -CRPS I,II Opioids TCA/SSRI -Phantom limb pain Muscle relaxants Gabapentin Aniline deriv. Opioids Anticonvulsants Antidepressants Multimodalities Interventions Antidepressants Psychological therapy Psychotherapy Interventions Multimodalities Acute Postoperative Pain ผู้ป่วยมีอาการปวดเฉียบพลัน “5th Vital sign” มีสาเหตุที่ท าให้เกิดอาการปวด รักษาสาเหตุ ประเมินระดับความปวด ไม่ต้องการ อาการปวดต้องการการรักษาหรือไม่ ประเมินซ ้าและบันทึก ต้องการ (PS ≥ 4 หรือปวดปานกลางขึ้นไป) เครื่องมือที่ใช้ประเมินความปวด รักษาโดยใช้ยา - VAS/VRS/NRS รักษาโดยไม่ใช้ยา - FACE/FLACCs รักษาแบบผสมผสาน - CHEOPS ไม่ได้ผล การรักษาได้ผลดีหรือไม่ ปรึกษาผู้เชี่ยวชาญ ได้ผลดี เกิด เกิดภาวะแทรกซ้อนจากการรักษาหรือไม่
    [Show full text]